BG
CRL icon

Bellevue Group’s Charles River Laboratories CRL Stock Holding History

Bellevue Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,327
Closed -$9.29M – 153
2024
Q4 		$9.29M Sell
50,327
-22,788
-31% -$4.39M 0.18% 81
2024
Q3 		$14.4M Sell
73,115
-159,587
-69% -$33.2M 0.23% 82
2024
Q2 		$48.1M Buy
232,702
+3,005
+1% +$681K 0.78% 32
2024
Q1 		$62.2M Buy
229,697
+11,941
+5% +$2.85M 0.95% 30
2023
Q4 		$51.5M Sell
217,756
-11,586
-5% -$2.28M 0.79% 38
2023
Q3 		$44.9M Sell
229,342
-85,171
-27% -$17.5M 0.72% 40
2023
Q2 		$66.1M Buy
314,513
+12,067
+4% +$2.4M 0.94% 32
2023
Q1 		$61M Buy
302,446
+12,469
+4% +$2.83M 0.89% 38
2022
Q4 		$63.2M Buy
289,977
+26,984
+10% +$5.89M 0.84% 36
2022
Q3 		$51.8M Buy
262,993
+31,924
+14% +$6.89M 0.74% 43
2022
Q2 		$49.4M Buy
231,069
+104,663
+83% +$25.6M 0.7% 46
2022
Q1 		$35.9M Buy
126,406
+60,495
+92% +$18.7M 0.42% 73
2021
Q4 		$24.8M Buy
65,911
+2,582
+4% +$1M 0.26% 95
2021
Q3 		$26.1M Sell
63,329
-114,941
-64% -$47.7M 0.27% 96
2021
Q2 		$65.9M Sell
178,270
-10,115
-5% -$3.38M 0.64% 54
2021
Q1 		$54.6M Buy
188,385
+45,367
+32% +$12.6M 0.58% 55
2020
Q4 		$35.7M Sell
143,018
-208,065
-59% -$49.6M 0.41% 70
2020
Q3 		$79.5M Sell
351,083
-14,750
-4% -$3.06M 1.1% 26
2020
Q2 		$63.8M Buy
365,833
+34,210
+10% +$5.46M 0.9% 29
2020
Q1 		$41.9M Buy
331,623
+48,525
+17% +$7.28M 0.81% 35
2019
Q4 		$43.2M Buy
283,098
+274,798
+3,311% +$38M 0.69% 42
2019
Q3 		$1.1M Buy
+8,300
New +$1.11M 0.02% 141

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group's CRL Position: Q1 2025 in Review

Bellevue Group sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 50,327 shares — an estimated $9.29M sold.

Bellevue Group first reported a position in CRL in Q3 2019 and held it in 22 quarters. The position peaked at $79.5M in Q3 2020. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Bellevue Group reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Bellevue Group sold 50,327 Charles River Laboratories shares in Q1 2025, an estimated $9.29M.
  • Bellevue Group first reported a position in Charles River Laboratories in Q3 2019 and held it in 22 quarters.
  • Bellevue Group's Charles River Laboratories position peaked at $79.5M in Q3 2020.
  • 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.